Literature DB >> 12508954

New pharmacological tools for obesity.

E Nisoli1, M O Carruba.   

Abstract

Obesity is a multi-factorial, chronic disorder that has reached epidemic proportions in most industrialized countries and is threatening to become a global epidemic. Obese patients are at a higher risk from coronary artery disease, hypertension, hyperlipidemia, diabetes mellitus, certain cancers, cerebrovascular accidents, osteoarthritis, restrictive pulmonary disease, and sleep apnea. Obesity is a particularly challenging clinical condition to treat, because of its complex pathophysiological basis. Indeed, body weight represents the integration of many biological and environmental components. Efforts to develop innovative anti-obesity drugs have been recently intensified. In broad terms, researchers use different distinct strategies: first, to reduce energy intake; second, to increase energy expenditure; third, to alter the partitioning of nutrients between fat and lean tissue. In the present review we concentrate on the first of these strategies, by underlining the new pharmacological tools which are presently studied.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12508954     DOI: 10.1007/BF03344055

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  81 in total

1.  Central administration of oleic acid inhibits glucose production and food intake.

Authors:  Silvana Obici; Zhaohui Feng; Kimyata Morgan; Daniel Stein; George Karkanias; Luciano Rossetti
Journal:  Diabetes       Date:  2002-02       Impact factor: 9.461

2.  A frameshift mutation in human MC4R is associated with a dominant form of obesity.

Authors:  C Vaisse; K Clement; B Guy-Grand; P Froguel
Journal:  Nat Genet       Date:  1998-10       Impact factor: 38.330

Review 3.  Pharmaceutical treatment of obesity.

Authors:  G L Blackburn; D Miller; S Chan
Journal:  Nurs Clin North Am       Date:  1997-12       Impact factor: 1.208

4.  Normal feeding behavior, body weight and leptin response require the neuropeptide Y Y2 receptor.

Authors:  P Naveilhan; H Hassani; J M Canals; A J Ekstrand; A Larefalk; V Chhajlani; E Arenas; K Gedda; L Svensson; P Thoren; P Ernfors
Journal:  Nat Med       Date:  1999-10       Impact factor: 53.440

5.  Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.

Authors:  L A Scrocchi; T J Brown; N MaClusky; P L Brubaker; A B Auerbach; A L Joyner; D J Drucker
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

Review 6.  Medical hazards of obesity.

Authors:  F X Pi-Sunyer
Journal:  Ann Intern Med       Date:  1993-10-01       Impact factor: 25.391

7.  Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.

Authors:  W P James; A Astrup; N Finer; J Hilsted; P Kopelman; S Rössner; W H Saris; L F Van Gaal
Journal:  Lancet       Date:  2000 Dec 23-30       Impact factor: 79.321

Review 8.  The ciliary neurotrophic factor and its receptor, CNTFR alpha.

Authors:  M W Sleeman; K D Anderson; P D Lambert; G D Yancopoulos; S J Wiegand
Journal:  Pharm Acta Helv       Date:  2000-03

9.  Activation of insulin signal transduction pathway and anti-diabetic activity of small molecule insulin receptor activators.

Authors:  S A Qureshi; V Ding; Z Li; D Szalkowski; D E Biazzo-Ashnault; D Xie; R Saperstein; E Brady; S Huskey; X Shen; K Liu; L Xu; G M Salituro; J V Heck; D E Moller; A B Jones; B B Zhang
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

10.  Localization of the melanocortin-4 receptor (MC4-R) in neuroendocrine and autonomic control circuits in the brain.

Authors:  K G Mountjoy; M T Mortrud; M J Low; R B Simerly; R D Cone
Journal:  Mol Endocrinol       Date:  1994-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.